Core Viewpoint - The company reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and growth in key product sales [1] Financial Performance - The company achieved a revenue of approximately 307 million yuan, representing a year-on-year growth of 17.59% [1] - The net profit attributable to the parent company was around 107 million yuan, reflecting a year-on-year increase of 57.61% [1] - The net profit excluding non-recurring gains and losses was approximately 93 million yuan, which is a 75.45% increase compared to the same period last year [1] Operational Drivers - The increase in revenue was primarily driven by higher sales volumes of core products ARA and algal oil DHA [1] - Profit growth was attributed to the rise in revenue, improved production efficiency, and optimization of product and customer structures, enhancing the company's profitability [1]

Core Viewpoint - The article discusses the emerging significance of Extracellular Matrix (ECM) in anti-aging skincare, highlighting the potential of N-acetylneuraminic acid (also known as "Nectar Acid") as a key ingredient in this new approach to skincare [2][3][15]. Group 1: ECM and Anti-Aging - ECM has been identified as the thirteenth hallmark of aging, representing a new pathway for anti-aging technology in the beauty industry [2][8]. - Major beauty companies like L'Oréal, Estée Lauder, Shiseido, and others are actively investing in ECM-related research and development, indicating a competitive landscape [8][11]. Group 2: N-acetylneuraminic Acid (Nectar Acid) - N-acetylneuraminic acid has recently been approved by the National Medical Products Administration in China, marking its transition from experimental to a recognized cosmetic ingredient [3][15]. - This ingredient exhibits multiple biological activities, including anti-wrinkle, brightening, anti-inflammatory properties, and the ability to regulate ECM homeostasis [15][22]. Group 3: Mechanisms and Efficacy - N-acetylneuraminic acid significantly enhances collagen gene promoter activity, leading to a 252% increase in type I collagen synthesis at a concentration of 0.2% [18]. - It acts as a stabilizer for ECM by neutralizing reactive oxygen species (ROS) and inhibiting matrix metalloproteinases (MMP-1, MMP-3, MMP-9), thereby reducing collagen degradation [20][22]. Group 4: Market Potential and Applications - The successful incorporation of N-acetylneuraminic acid into the cosmetic ingredient directory opens up new market opportunities and enhances its commercial value [26][27]. - The ingredient's dual application in both topical and oral beauty products aligns with traditional Asian wellness practices, providing a strong foundation for cross-category integration [26][28]. Group 5: Research and Development - The company has invested over 30 million yuan in the industrialization of N-acetylneuraminic acid, overcoming traditional extraction challenges to achieve high purity and yield [28][29]. - Ongoing research focuses on multi-omics studies to validate the ingredient's efficacy across various biological pathways, enhancing its appeal in the anti-aging market [25][34].

嘉必优生物技术（武汉）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 证券代码：688089 证券简称：嘉必优 公告编号：2025-055 ? 股东持股的基本情况 截止本公告披露日，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）股东马涛先生持有公司股份 157,373 股，占公司总股本的 0.0935%。其中 易买入股份，34,392 股来源于公司 2022 年度资本公积转增股本，均为无限售流 通股。 ? 减持计划的主要内容 马涛先生因个人资金需求，拟于减持计划披露之日起 15 个交易日后的 3 个 月内通过集中竞价方式减持其所持有的公司股份，合计数量不超过 150,000 股， 即不超过公司总股本的 0.0891%。 ? 特别说明 马涛先生系原公司第三届高级管理人员，现已卸任高级管理人员职位届满 6 个月，按照现行法律法规要求无需披露减持计划，但因公司拟并购上海欧易生物 医学科技有限公司 63.2134%股权项目签署了承诺函："自本次交易复牌之日起 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-055 嘉必优生物技术（武汉）股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截止本公告披露日，嘉必优生物技术（武汉）股份有限公司（以下简称"公 司"）股东马涛先生持有公司股份 157,373 股，占公司总股本的 0.0935%。其中 85,981 股来源于公司首次公开发行前取得，37,000 股来源于二级市场集中竞价交 易买入股份，34,392 股来源于公司 2022 年度资本公积转增股本，均为无限售流 通股。 上述减持主体无一致行动人。 二、减持计划的主要内容 | 股东名称 | 马涛 | | | | | | --- | --- | --- | --- | --- | --- | | 计划减持数量 | 不超过：150,000 股 | | | | | | 计划减持比例 | 不超过：0.0891% | | | | | | 减持方式及对应减持数 量 | 股 集中竞价减持，不超过：15 ...

嘉必优公告，股东马涛因个人资金需求，计划于2025年7月29日至2025年10月28日期间，通过集中竞价 方式减持不超过15万股，占公司总股本的0.0891%。马涛先生目前持有公司股份15.74万股，占公司总股 本的0.0935%。 ...

Group 1 - The stock price of Jia Bi You (688089) closed at 25.13 yuan on July 4, 2025, up 0.44% from the previous week [1] - The company's market capitalization is currently 4.23 billion yuan, ranking 93rd out of 169 in the chemical products sector and 3463rd out of 5149 in the A-share market [1] - The company announced a cash dividend of 0.20094 yuan per share, with the record date on July 9, 2025, and the payment date on July 10, 2025, totaling approximately 33.66 million yuan distributed among 167,519,992 shares [1] Group 2 - The company adjusted the upper limit for the second phase of share repurchase from 25.00 yuan to 24.80 yuan per share, effective from July 10, 2025 [2] - As of June 30, 2025, the company has not yet repurchased any shares through its dedicated securities account, with the repurchase plan initially disclosed on January 25, 2025, and an expected amount between 15 million and 30 million yuan [2][3]

Core Viewpoint - The company has announced a differentiated cash dividend distribution plan, proposing a cash dividend of 0.20094 yuan per share, which was approved at the 2024 annual shareholders' meeting on May 29, 2025 [1][2][3]. Dividend Distribution Plan - The cash dividend of 0.20094 yuan per share is inclusive of tax, and the total number of shares eligible for distribution is 167,519,992 after deducting 789,128 shares held in the company's repurchase account from the total share capital of 168,309,120 shares [2][3]. - The company will not issue bonus shares or increase capital reserves, and the remaining undistributed profits will be carried forward to future years [2][3]. Ex-Dividend Date and Payment Date - The relevant dates for the dividend distribution include the record date, ex-dividend date, and cash dividend payment date, which are specified in the announcement [3]. Taxation on Dividends - For individual shareholders and securities investment funds, the cash dividend of 0.20094 yuan per share will not be subject to withholding personal income tax at the time of distribution. Tax will be calculated based on the holding period when the shares are sold [5][6]. - For qualified foreign institutional investors (QFIIs), a 10% corporate income tax will be withheld, resulting in an actual cash dividend of 0.18085 yuan per share [6]. - Hong Kong investors will also have a 10% withholding tax applied, with the same actual cash dividend of 0.18085 yuan per share, and they may apply for tax treaty benefits if applicable [6]. Implementation of Dividend Distribution - The company will distribute dividends through China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders who have registered their shares by the record date [3][7]. - Shares held in the company's repurchase account will not participate in the profit distribution [3].

Core Viewpoint - The legal opinion issued by Beijing Zhonglun Law Firm confirms that the differentiated dividend distribution plan proposed by Jia Biyou Biotechnology (Wuhan) Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [6][11][12]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.20094 RMB per share, totaling approximately 33.66 million RMB, calculated on a base of 167,519,992 shares after deducting repurchased shares [9][10]. - The company has repurchased 789,128 shares, and the total share capital is 168,309,120 shares, which affects the calculation of the dividend distribution [10][11]. - The company will not conduct capital reserve transfers or issue bonus shares, with any remaining undistributed profits carried forward to future years [11]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and facts provided by the company, ensuring the accuracy and completeness of the legal opinion [4][5]. - The legal opinion is based on existing laws, regulations, and the company's articles of association, confirming that the differentiated dividend distribution does not violate any legal provisions [6][12]. - The law firm emphasizes that the opinion is solely for the purpose of the differentiated dividend distribution and cannot be used for any other purpose without consent [5][12].

证券代码：688089 证券简称：嘉必优 公告编号：2025-053 嘉必优生物技术（武汉）股份有限公司 关于第二期以集中竞价交易方式回购公司股份的进展公告 一、回购股份的基本情况 2025 年 1 月 24 日，公司召开第四届董事会第二次会议，审议通过了《关于 第二期以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金 和回购专项贷款以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票，并在未来适宜时机用于实施股权激励计划，回购资金总额不低于人民币 1,500 万元（含），不超过人民币 3,000 万元（含），回购价格不超过 25.00 元/股 （含），回购股份的期限为自公司董事会审议通过本次回购方案之日起不超过 12 个 月 。 具 体 内 容 详 见 公 司 于 2025 年 2 月 7 日 在 上 海 证 券 交 易 所 网 站 (www.sse.com.cn)上披露的《嘉必优生物技术（武汉）股份有限公司关于第二期 以集中竞价交易方式回购公司股份的回购报告书》（公告编号：2025-008）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管 ...

证券代码：688089 证券简称：嘉必优 公告编号：2025-054 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年年度利润分配 方案的议案》，公司 2024 年度以实施权益分派股权登记日登记的公司总股本扣除 公司回购专用证券账户中股份为基数，向全体股东每股派发现金红利 0.20094 元 调整前回购价格上限：不超过人民币 25.00 元/股（含） 调整后回购价格上限：不超过人民币 24.80 元/股（含） 回购价格上限调整起始日：2025 年 7 月 10 日（公司 2024 年年度权益分 派除权除息日） （含税）。本次权益分派的股权登记日为 2025 年 7 月 9 日，除权除息日为 2025 年 7 月 10 日，具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn） 披露的《嘉必优生物技术（武汉）股份有限公司 2024 年年度权益分派实施公告》 （公告编号：2025-052）。 上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、回购股份的基本情况 ...